Newron Pharma Raises €30 Million

ItalianCNS drug-discovery firm Newron Pharmaceuticals said last week that it has raised €30 million ($39.8 million) in venture capital funding.

HBM Partners, on behalf of HBM BioCapital and HBM Bioventures, led the financing round. Existing investors 3i Group, Apax Partners, and Atlas Ventures all participated in the round, as well.

Newron said that approximately €23 million in funding closed last week, while the remaining €7 million would remain open for a few weeks.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.